1,300 results on '"Han, Baohui"'
Search Results
102. Prediction of lymph node status in completely resected IIIa/N2 small cell lung cancer: importance of subcarinal station metastases
103. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
104. Prognostic value of pretreatment procalcitonin and neutrophil– lymphocyte ratio in extensive-stage small-cell lung cancer
105. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
106. Neoadjuvant Immunotherapy for Patients With Non–Small Cell Lung Cancer—Is a New Era Coming?
107. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
108. Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study
109. Flow Stokes Microscopy for High Throughput Classification of Marine Particles
110. Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
111. Extracellular vesicle long RNA markers of early‐stage lung adenocarcinoma
112. Hypomethylation of RPTOR in peripheral blood is associated with very early-stage lung cancer
113. The indication of completion lobectomy for lung adenocarcinoma ≤3 cm after wedge resection during surgical operation
114. The Advent of Ultra-high Volume Thoracic Surgical Centers in Shanghai
115. Predicting the recurrence risk factors and clinical outcomes of peripheral pulmonary adenocarcinoma ≤3 cm with wedge resection
116. Efficacy and safety of anlotinib combined with PD ‐1/ PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
117. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
118. PD-L1 on lymphatic endothelium inside tumor: a novel predictor for the efficacy of anti-angiogenesis (anlotinib) plus anti-PD-L1 antibody
119. Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer
120. Novel Association Between CD74 Polymorphisms and Hematologic Toxicity in Patients With NSCLC After Platinum-Based Chemotherapy
121. Utility of endobronchial ultrasound‐guided transbronchial needle aspiration in diagnosing non‐specific inflammatory intrathorcacic lymphadenitis
122. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB
123. Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma
124. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China
125. Lentivirus-mediated knockdown of CTDP1 inhibits lung cancer cell growth in vitro
126. Screening anlotinib responders via blood‐based proteomics in non‐small cell lung cancer
127. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study
128. Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
129. Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.
130. Outcomes of sintilimab plus pemetrexed and platinum (SPP) according to stage of disease in patients (pts) with locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase 3 ORIENT-11 study.
131. Phase Ib/IIa study evaluating the safety and clinical activity of osimeritinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients (AUTOMAN).
132. Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial
133. China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016 version)
134. Extracellular vesicle long RNA markers of early‐stage lung adenocarcinoma.
135. Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer.
136. Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients
137. Pseudomonas aeruginosa preparation plus chemotherapy for advanced non-small-cell lung cancer: a randomized, multicenter, double-blind phase III study
138. Wnt signaling regulates the stemness of lung cancer stem cells and its inhibitors exert anticancer effect on lung cancer SPC-A1 cells
139. Mitofusin-2 over-expresses and leads to dysregulation of cell cycle and cell invasion in lung adenocarcinoma
140. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma
141. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice
142. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
143. Correction to: Epidermal Growth Factor Receptor (EGFR)–Tyrosine Kinase Inhibitors (TKIs) Combined with Chemotherapy Delay Brain Metastasis in Patients with EGFR‑Mutant Lung Adenocarcinoma
144. Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial
145. The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma
146. Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
147. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
148. Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals
149. Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
150. Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.